Pictured from left, Benoit Gravel, VP Sanofi Canada; Larry Sidel, VP and COO, JGH Foundation; Myer Bick, President and CEO, JGH Foundation; Jon Fairest, President and CEO, Sanofi Canada; Dr. Susan Kahn, Director, ...
Centre created in partnership with Sanofi Canada
MONTREAL, Dec. 18, 2012 /CNW Telbec/ - In partnership with Sanofi
Canada, the Jewish General Hospital (JGH) has created the Centre of
Excellence in Thrombosis and Anticoagulation Care (CETAC). The Centre's
mandate is to provide leadership and guidance to other institutions and
agencies in Quebec to support initiatives in thrombosis prevention and
treatment. Funding of the Centre is made possible through support from
the JGH Foundation and a $1 million contribution from Sanofi Canada
over 4 years.
Complications of thrombosis, the formation of blood clots inside a blood
vessel, can include deep vein thrombosis (DVT), pulmonary embolism (PE)
and venous thromboembolism (VTE).
"VTE is the third most common cardiovascular condition after heart
attack and stroke," says Dr. Susan Kahn, Director of the JGH Thrombosis
Program. "In addition, PE causes more deaths each year than breast
cancer, HIV and motor vehicle accidents combined. These complications
are serious health issues, which must be addressed in an organized
fashion in an appropriate facility. Our new Centre will be the right
place to show leadership in thrombosis and anticoagulation care."
The Centre's partnership is the latest of many collaborations between
the JGH and government, other hospitals, healthcare and research
institutions, and private industry.
"Our partnership with the private sector and others enables the JGH to
achieve much more than would have been possible for us on our own,"
says Dr. Hartley Stern, JGH Executive Director. "It represents our
ongoing commitment to working within the Quebec healthcare network and
becoming a valuable resource to improve health care throughout Montreal
"We are delighted to be involved with the JGH's Centre of Excellence,"
says Sanofi Canada President and CEO Jon Fairest. "With a strategy of
cooperation that targets unmet medical needs, we continue to forge
strong relationships with scientific communities and experts
acknowledged in their fields to improve therapies and support patients
and their families."
The Centre will focus not only on treatment but also on prevention,
which means better long-term health for many individuals, but also less
financial pressure on the overburdened public healthcare system.
About the JGH Thrombosis Program
The current JGH Thrombosis Program encompasses a broad range of clinical
and research activities that relate to diagnosis, risk factors,
treatment of venous and arterial thromboembolic disease, management of
thrombophilia and issues pertaining to long-term anticoagulation. Over
the last 15 years the JGH has built a unique, multidisciplinary
thrombosis program with patient care, training, education and
internationally recognized research components that are unparalleled in
Quebec and among the top programs in Canada. The Thrombosis physicians
comprise a multidisciplinary, collaborative group that includes
hematologists, internists and a pulmonologist, with close links to
related specialties such as vascular surgery, cardiology, neurology and
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs,
consumer healthcare, emerging markets, animal health and the new
Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York
Sanofi companies in Canada include sanofi-aventis Canada Inc.
(pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health
(health and beauty), Genzyme (rare diseases) and Merial (animal
health). Together they employ more than 1,700 people, mainly in the
greater Montreal and Toronto areas. In 2011 Sanofi companies invested
$151.7 million in R&D in Canada, creating jobs, business and
opportunity throughout the country.
Image with caption: "Pictured from left, Benoit Gravel, VP Sanofi Canada; Larry Sidel, VP and COO, JGH Foundation; Myer Bick, President and CEO, JGH Foundation; Jon Fairest, President and CEO, Sanofi Canada; Dr. Susan Kahn, Director, JGH Thrombosis Program; Dr. Hartley Stern, Executive Director, Jewish General. (CNW Group/SANOFI)". Image available at: http://photos.newswire.ca/images/download/20121218_C9988_PHOTO_EN_22050.jpg
For further information:
Glenn J. Nashen, Director
Astrid Morin, Media Relations
Public Affairs and Communications
Jewish General Hospital
Tel.: 514-340-8222 ext. 4612
Tel. 514 956-4188